Gene Expression in Blood of Subjects with Duchenne Muscular Dystrophy

Overview

Journal Neurogenetics

Specialty Neurology

Date 2008 Dec 11

PMID 19067001

Citations 9

Authors

Brenda Wong

Donald L Gilbert

Wynn L Walker

Isaac H Liao

Lisa Lit

Boryana Stamova

Glen Jickling

Michelle Apperson

Frank R Sharp

Affiliations

Soon will be listed here.

Abstract

The objective of this study was to examine RNA expression in blood of subjects with Duchenne muscular dystrophy (DMD). Whole blood was collected into PAX gene tubes and RNA was isolated for 3- to 20-year-old males with DMD (n = 34) and for age- and gender-matched normal healthy controls (n = 21). DMD was confirmed by genetic testing in all subjects. RNA expression was measured on Affymetrix whole-genome human U133 Plus 2.0 GeneChips. Using a Benjamini-Hochberg false discovery rate of 0.05 to correct for multiple comparisons, an unpaired t test for DMD versus controls yielded 10,763 regulated probes with no fold change cutoff, 1,467 probes with >|1.5|-fold change, 191 probes with >|2.0|-fold change, and 59 probes with a >|2.5|-fold change. These genes (probes) separated DMD from controls using cluster analyses. Almost all of the genes regulated in peripheral blood were different from the genes reported to be regulated in diseased muscle of subjects with DMD. It is proposed that the genes regulated in blood of subjects with Duchenne muscular dystrophy are indicative, at least in part, of the immune response to the diseased DMD muscle. The regulated genes might be used to monitor therapy or provide novel targets for immune-directed therapy for DMD.

Citing Articles

Peripheral blood transcriptome profiling enables monitoring disease progression in dystrophic mice and patients.

Signorelli M, Ebrahimpoor M, Veth O, Hettne K, Verwey N, Garcia-Rodriguez R EMBO Mol Med. 2021; 13(4):e13328.

PMID: 33751844 PMC: 8033515. DOI: 10.15252/emmm.202013328.

Evaluation of blood gene expression levels in facioscapulohumeral muscular dystrophy patients.

Signorelli M, Mason A, Mul K, Evangelista T, Mei H, Voermans N Sci Rep. 2020; 10(1):17547.

PMID: 33067535 PMC: 7567883. DOI: 10.1038/s41598-020-74687-5.

Biomarkers of Duchenne muscular dystrophy: current findings.

Szigyarto C, Spitali P Degener Neurol Neuromuscul Dis. 2018; 8:1-13.

PMID: 30050384 PMC: 6053903. DOI: 10.2147/DNND.S121099.

MicroRNA and mRNA Expression Changes in Steroid Naïve and Steroid Treated DMD Patients.

Liu D, Stamova B, Hu S, Ander B, Jickling G, Zhan X J Neuromuscul Dis. 2016; 2(4):387-396.

PMID: 27858746 PMC: 5240570. DOI: 10.3233/JND-150076.

Unveiling transcription factor regulation and differential co-expression genes in Duchenne muscular dystrophy.

Tian L, Cao J, Deng X, Zhang C, Qian T, Song X Diagn Pathol. 2014; 9:210.

PMID: 25338682 PMC: 4312468. DOI: 10.1186/s13000-014-0210-z.

References

Haslett J, Sanoudou D, Kho A, Han M, Bennett R, Kohane I . Gene expression profiling of Duchenne muscular dystrophy skeletal muscle. Neurogenetics. 2003; 4(4):163-71. DOI: 10.1007/s10048-003-0148-x. View

Walker W, Liao I, Gilbert D, Wong B, Pollard K, McCulloch C . Empirical Bayes accomodation of batch-effects in microarray data using identical replicate reference samples: application to RNA expression profiling of blood from Duchenne muscular dystrophy patients. BMC Genomics. 2008; 9:494. PMC: 2576259. DOI: 10.1186/1471-2164-9-494. View

Bromberg M, Wald J, Forshew D, Feldman E, Albers J . Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci. 1997; 150(1):59-62. DOI: 10.1016/s0022-510x(97)05370-7. View

Spencer M, Tidball J . Do immune cells promote the pathology of dystrophin-deficient myopathies?. Neuromuscul Disord. 2001; 11(6-7):556-64. DOI: 10.1016/s0960-8966(01)00198-5. View

Raju R, Dalakas M . Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain. 2005; 128(Pt 8):1887-96. DOI: 10.1093/brain/awh518. View

Tibshirani R, Hastie T, Narasimhan B, Chu G . Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A. 2002; 99(10):6567-72. PMC: 124443. DOI: 10.1073/pnas.082099299. View

Verde I, Pahlke G, Salanova M, Zhang G, Wang S, Coletti D . Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem. 2001; 276(14):11189-98. DOI: 10.1074/jbc.M006546200. View

Gaud A, Simon J, Witzel T, Carre-Pierrat M, Wermuth C, Segalat L . Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. Neuromuscul Disord. 2004; 14(6):365-70. DOI: 10.1016/j.nmd.2004.02.011. View

Tusher V, Tibshirani R, Chu G . Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001; 98(9):5116-21. PMC: 33173. DOI: 10.1073/pnas.091062498. View

10.

Tang Y, Xu H, Du X, Lit L, Walker W, Lu A . Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab. 2006; 26(8):1089-102. DOI: 10.1038/sj.jcbfm.9600264. View

11.

Inoue M, Wakayama Y, Kojima H, Shibuya S, Jimi T, Oniki H . Expression of myoferlin in skeletal muscles of patients with dysferlinopathy. Tohoku J Exp Med. 2006; 209(2):109-16. DOI: 10.1620/tjem.209.109. View

12.

Sundaram J, Rao V, Meena A, Anandaraj M . Altered expression, intracellular distribution and activity of lymphocyte calpain II in Duchenne muscular dystrophy. Clin Chim Acta. 2006; 373(1-2):82-7. DOI: 10.1016/j.cca.2006.05.004. View

13.

Gussoni E, Pavlath G, Miller R, Panzara M, Powell M, Blau H . Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy. J Immunol. 1994; 153(10):4798-805. View

14.

Tidball J, Wehling-Henricks M . Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. Curr Opin Rheumatol. 2005; 17(6):707-13. DOI: 10.1097/01.bor.0000179948.65895.1a. View

15.

Rando T . The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve. 2001; 24(12):1575-94. DOI: 10.1002/mus.1192. View

16.

Guzzo R, Salih M, Moore E, Tuana B . Molecular properties of cardiac tail-anchored membrane protein SLMAP are consistent with structural role in arrangement of excitation-contraction coupling apparatus. Am J Physiol Heart Circ Physiol. 2004; 288(4):H1810-9. DOI: 10.1152/ajpheart.01015.2004. View

17.

Ransohoff D . Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer. 2004; 4(4):309-14. DOI: 10.1038/nrc1322. View

18.

Langenbach K, Rando T . Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve. 2002; 26(5):644-53. DOI: 10.1002/mus.10258. View

19.

Moxley 3rd R, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K . Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2005; 64(1):13-20. DOI: 10.1212/01.WNL.0000148485.00049.B7. View

20.

Du X, Tang Y, Xu H, Lit L, Walker W, Ashwood P . Genomic profiles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: comparisons to ischemic stroke, migraine, and Tourette syndrome. Genomics. 2006; 87(6):693-703. DOI: 10.1016/j.ygeno.2006.02.003. View